Frank Rizzo, CEO of XenaCare Holdings, said: "We are extremely enthusiastic about this product, as it represents one of the first non-narcotic treatments for chronic pain. As we move towards our August launch, we plan to release full details about the product as well as its potential to compete effectively with current opiate-based drugs available on the market."
Recently, XenaCare has announced the launch of the SunPill, a dietary supplement that helps the skin protect itself from the harmful rays of the sun. The SunPill is currently available at RiteAid, CVS.com Drugstore.com and Amazon.com and many other mass retailers.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index